Heron Therapeutics Inc. (NASDAQ:HRTX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday.

According to Zacks, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. “

Other analysts have also issued reports about the company. Leerink Swann set a $34.00 price objective on Heron Therapeutics and gave the company a “buy” rating in a report on Saturday, October 8th. Cantor Fitzgerald reissued a “buy” rating and issued a $41.00 price objective on shares of Heron Therapeutics in a report on Wednesday, August 3rd. Brean Capital reissued a “buy” rating and issued a $55.00 price objective on shares of Heron Therapeutics in a report on Saturday, August 13th. Jefferies Group reissued a “buy” rating and issued a $46.00 price objective on shares of Heron Therapeutics in a report on Wednesday, July 27th. Finally, JMP Securities reissued a “buy” rating on shares of Heron Therapeutics in a report on Wednesday, November 9th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $41.63.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics (NASDAQ:HRTX) traded up 0.30% during mid-day trading on Wednesday, reaching $16.55. The company’s stock had a trading volume of 549,201 shares. Heron Therapeutics has a 52 week low of $13.95 and a 52 week high of $31.32. The firm has a 50-day moving average of $16.63 and a 200-day moving average of $18.03.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Tuesday, November 8th. The biotechnology company reported ($1.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.17) by $0.07. On average, equities analysts predict that Heron Therapeutics will post ($4.50) EPS for the current fiscal year.

Several institutional investors have recently modified their holdings of the company. Jacobs Levy Equity Management Inc. acquired a new position in shares of Heron Therapeutics during the first quarter valued at about $734,000. Panagora Asset Management Inc. increased its position in shares of Heron Therapeutics by 90.3% in the first quarter. Panagora Asset Management Inc. now owns 245,392 shares of the biotechnology company’s stock valued at $4,660,000 after buying an additional 116,461 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Heron Therapeutics by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 147,986 shares of the biotechnology company’s stock valued at $2,672,000 after buying an additional 4,579 shares in the last quarter. California State Teachers Retirement System increased its position in shares of Heron Therapeutics by 7.6% in the second quarter. California State Teachers Retirement System now owns 66,632 shares of the biotechnology company’s stock valued at $1,203,000 after buying an additional 4,732 shares in the last quarter. Finally, Swiss National Bank increased its position in shares of Heron Therapeutics by 3.0% in the second quarter. Swiss National Bank now owns 51,900 shares of the biotechnology company’s stock valued at $937,000 after buying an additional 1,500 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be read at https://www.thecerbatgem.com/2016/11/23/heron-therapeutics-inc-hrtx-upgraded-to-hold-by-zacks-investment-research.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

5 Day Chart for NASDAQ:HRTX

Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.